Welcome to our dedicated page for Tyme Technologies news (Ticker: TYME), a resource for investors and traders seeking the latest updates and insights on Tyme Technologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tyme Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tyme Technologies's position in the market.
Tyme Technologies, Inc. (NASDAQ: TYME) has announced that an abstract detailing clinical data for its lead candidate, oral SM-88, has been selected for presentation at the ASCO Virtual 2021 Gastrointestinal Cancers Symposium from January 15-17, 2021. The study focuses on SM-88's effectiveness in treating metastatic pancreatic cancer, showcasing encouraging responses across various cancers with minimal serious adverse events. This pivotal trial evaluates safety and efficacy for patients who have failed previous therapies, highlighting Tyme's innovative approach in cancer treatment.
Tyme Technologies, Inc. (NASDAQ: TYME) has appointed Richie Cunningham as its new Chief Executive Officer, effective November 24, 2020. Cunningham brings over 20 years of experience in the biopharmaceutical industry, having previously served as CEO at Icagen and in key roles at Boehringer Ingelheim. Steve Hoffman continues as Chairman of the board and Chief Science Officer. The leadership transition is expected to enhance TYME's strategic objectives in developing cancer metabolism-based therapies (CMBTs). Cunningham's expertise is deemed crucial for commercializing TYME's next-generation compounds.
Tyme Technologies, Inc. (NASDAQ: TYME) announced its Q2 2021 financial results, reporting a cash position of approximately $19.4 million, down from $21.3 million in Q1. The operational cash burn rate remained stable at $6.6 million. Significant developments included the orphan drug designation for SM-88 in treating pancreatic cancer and ongoing clinical trials in various cancer types and COVID-19. Future expectations include crucial trial data readouts and the initiation of new trials. The company is advancing its cancer metabolism-based therapies amid the uncertainties posed by COVID-19.
Tyme Technologies, Inc. (NASDAQ: TYME) will present at the Jefferies Virtual Global Healthcare Conference from November 17-19, highlighting growth opportunities in cancer metabolism therapies. Key topics include late-stage trials of SM-88 in pancreatic cancer, and trials for ultra-rare sarcoma and COVID-19 treatments. The company aims to leverage advances in cancer cell metabolism with a focus on therapies including SM-88, TYME-18, and TYME-19. The presentation will be available on their website.
FAQ
What is the market cap of Tyme Technologies (TYME)?
